(Q40844396)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Andrea B. Troxel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Changqing Ma

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Stephen J Stopenski

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Waixing Tang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Aaron B Cohen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Marina Pappas-Paxinos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Burles A Johnson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Emerson Y Chen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Michael D Feldman

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Marcia S Brose

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

18 March 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

188-195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Phase II trial of sorafenib in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Molecular analysis of thyroid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Phase II trial of sorafenib in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Sorafenib in metastatic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-016-0253-6

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26994002

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12672-016-0253-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26994002%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference